<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7480628\results\search\testTrace\results.xml">
  <result pre="reviewing the COVID-19 disease, including pathogen, clinical features, diagnosis, and" exact="treatment" post="with particular attention to cardiovascular involvement based on the"/>
  <result pre="early clinical outcome. At the moment, there is no specific" exact="treatment" post="for COVID-19, but multiple randomized controlled trials (RCT) are"/>
  <result pre="with a mortality rate around 10â€&quot;15% with no available proper" exact="treatment" post="or vaccination. Then emergence of another outbreak in 2012"/>
  <result pre="literature on COVID-19 disease, including pathogen, clinical features, diagnosis, and" exact="treatment" post="based on the current evidence, with emphasis on understanding"/>
  <result pre="understanding the mechanisms of cardiac involvement, cardiac complications, so that" exact="treatment" post="of these patients can be timely and effective and"/>
  <result pre="outcomes [27, 28]. A lso acute cardiac complications caused by" exact="infection" post="with the SARS-CoV-2, increases the difficulty and complexity of"/>
  <result pre="12.5â€‰days of contact [15, 23, 30]. A higher risk of" exact="infection" post="has been noticed in older patients, male sex, patients"/>
  <result pre="hypertension and malignancy [31]. Patients at any age can contract" exact="infection" post="with the SARS-CoV-2 and any system can be involved."/>
  <result pre="ranging from the common mild symptoms of upper respiratory tract" exact="infection" post="of fever, dry cough, dyspnea, myalgia, and fatigue to"/>
  <result pre="reported 3.4% global MR. Evaluation When treating patients with the" exact="diagnosis" post="of acute viral respiratory tract infection many differential diagnoses"/>
  <result pre="treating patients with the diagnosis of acute viral respiratory tract" exact="infection" post="many differential diagnoses related to atypical pathogens and common"/>
  <result pre="used to confirm the clinical diagnosis. For the most sensitive" exact="detection" post="of 2019-nCoV, bronchoalveolar lavage fluid specimens have the highest"/>
  <result pre="of 2019-nCoV, bronchoalveolar lavage fluid specimens have the highest positive" exact="detection" post="rate of 93%, followed by sputum 72%, and nasal"/>
  <result pre="rate of 93%, followed by sputum 72%, and nasal swabs" exact="detection" post="rate is 63%. Both fecal and blood specimens have"/>
  <result pre="only 29 and 1% of diseased patients. Regardless the high" exact="detection" post="rates in bronchoalveolar lavage fluid, the Center for Disease"/>
  <result pre="healthcare workers [21, 24]. Cardiac complications Myocardial damage caused by" exact="infection" post="with the SARS-CoV-2 undoubtedly increases the difficulty and complexity"/>
  <result pre="outcome [4, 28, 29]. Treatment Currently, there is no validated" exact="treatment" post="for COVID-19. Due to the emerging nature of COVID-19"/>
  <result pre="randomized controlled trials are showing the efficacy of a specific" exact="treatment" post="of the 2019-nCOV. The main strategies are symptomatic and"/>
  <result pre="data that indicated an increase of viral shedding [40]. However," exact="treatment" post="with methylprednisolone may be beneficial for patients who develop"/>
  <result pre="[47]. The current recommendation is to assess QT before starting" exact="treatment" post="and close monitoring in patients with additional risk factors"/>
  <result pre="[50]. Lopinavir/ritonavir are protease inhibitors that are approved for HIV-1" exact="infection" post="treatment. Prolongation of PR and QT intervals leading to"/>
  <result pre="confirmed severe COVID-19 disease. Researchers observed no survival benefit following" exact="treatment" post="with lopinavir/ritonavir in hospitalized adult patients with severe COVID-19"/>
  <result pre="may help to confirm or exclude the possibility of a" exact="treatment" post="benefit [51]. Remdesivir is a monophosphoramidate prodrug of an"/>
  <result pre="Ebola [45]. The safety and efficacy of remdesivir for the" exact="treatment" post="of COVID-19 are being evaluated in multiple ongoing Phase"/>
  <result pre="early clinical outcome. At the moment, there is no specific" exact="treatment" post="for COVID-19, but multiple RCT are being conducted. New"/>
  <result pre="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200512-covid-19-sitrep-113.pdf?sfvrsn=feac3b6d_2. 6.World Health Organization Clinical management of severe acute respiratory" exact="infection" post="when Novel coronavirus (nCoV) infection is suspected [EB/OL]. (2020-01-11)"/>
  <result pre="management of severe acute respiratory infection when Novel coronavirus (nCoV)" exact="infection" post="is suspected [EB/OL]. (2020-01-11) [2020-02-11] https://covid19-evidence.paho.org/handle/20.500.12663/431. 7.ZhuNZhangDWangWet al.A novel"/>
  <result pre="pneumonia in Wuhan, China. JAMA Intern Med. 2020. 10.1001/jamainternmed.2020.0994. 34.TangNBaiHChenXGongJLiDSunZAnticoagulant" exact="treatment" post="is associated with decreased mortality in severe coronavirus disease"/>
  <result pre="say doctors and scientistsBMJ.2020368m108610.1136/bmj.m108632184201 40.LeeNAllen ChanKCHuiDSet al.Effects of early corticosteroid" exact="treatment" post="on plasma SARS-associated coronavirus RNA concentrations in adult patientsJ"/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin"/>
  <result pre="JC, Parola P, et al. Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
  <result pre="44.ChanJFYaoYYeungMLet al.Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmosetJ Infect"/>
 </snippets>
</snippetsTree>
